Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1552627
PUBLISHER: Grand View Research | PRODUCT CODE: 1552627
Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Antipsychotic Drugs Market Growth & Trends:
The global antipsychotic drugs market size is expected to reach USD 24.97 billion by 2030, growing at CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The continuous development of better next-generation products to overcome adverse effects and unwanted reactions of existing products is creating demand for newer products. This factor is anticipated to propel the market.
Rapid growth of antipsychotics can be attributed to the rising prevalence of psychosis and other mental disorders. Governments are focused on creating awareness regarding mental health and psychological illnesses, which is further anticipated to drive the demand for antipsychotics. Government bodies in collaboration with major players conduct social programs to break the stigma related to psychotic disorders that exists in the society.
Adverse effects of antipsychotics, such as insomnia, dry mouth, drowsiness, and blurred vision, are expected to affect the growth by decreasing the level of acceptance in patients. In addition, the possibility of dependency, habit formation, or addiction is affecting the adoption of these drugs.
Established brands such as, Zyprexa lost patent protection in October 2011, followed by Seroquel and Risperdal in 2012, which hampers the market growth for these drugs. Also, the entry of generic versions of these products slowed the growth of the already existing brands.
Antipsychotic Drugs Market Report Highlights:
- Schizophrenia accounted for the largest market revenue share of 39.2% in 2023. Schizophrenia is a serious mental illness that impacts a significant amount of individuals worldwide.
- Aripiprazole accounted for the largest market revenue share in 2023. The sales of this segment increase with the adoption of third-generation products. Furthermore, it is anticipated that product approvals are expected to experience the most significant growth during the projected period.
- Brexpiprazole is expected to register the fastest CAGR of 9.8% during the forecast period.
- The second generation therapeutic class accounted for the largest market revenue share of 62.9% in 2023. The growth of this segment can be attributed to the presence of a number of second-generation medications available in the market, such as HAFYERA, INVEGA, SEROQUEL, XR, ZYPREXA, and others.
- The retail pharmacies segment dominated the market and accounted for the largest share in 2023. Retail pharmacies are easily available to patients, and they often act as the initial point of contact for individuals in need of prescription medications.
- North America dominated the market with revenue share of 37.67% in 2023. Some of the critical factors attributable to the region's market dominance include the strong prevalence of psychiatric illnesses in the region and the market presence of prominent biopharmaceutical companies.
Product Code: GVR-1-68038-408-6
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Antipsychotic Drugs Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Antipsychotic Drugs Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Antipsychotic Drugs Market: Disease Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Antipsychotic Drugs Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
- 4.3. Schizophrenia
- 4.3.1. Schizophrenia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Bipolar Disorder
- 4.4.1. Bipolar Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Unipolar Disorder
- 4.5.1. Unipolar Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Dementia
- 4.6.1. Dementia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.7. Others
- 4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Antipsychotic Drugs Market: Drug Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Antipsychotic Drugs Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
- 5.3. Risperidone
- 5.3.1. Risperidone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Quetiapine
- 5.4.1. Quetiapine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Olanzapine
- 5.5.1. Olanzapine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Aripiprazole
- 5.6.1. Aripiprazole Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Brexpiprazole
- 5.7.1. Brexpiprazole Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.8. Paliperidone Palmitate
- 5.8.1. Paliperidone Palmitate Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.9. Others
- 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Antipsychotic Drugs Market: Therapeutic Class Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Antipsychotic Drugs Market: Therapeutic Class Movement Analysis, 2023 & 2030 (USD Million)
- 6.3. First Generation
- 6.3.1. First Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Second Generation
- 6.4.1. Second Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Third Generation
- 6.5.1. Third Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Antipsychotic Drugs Market: Distribution Channel Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Antipsychotic Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
- 7.3. Hospital Pharmacies
- 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Retail Pharmacies
- 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Online Pharmacies
- 7.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Antipsychotic Drugs Market: Regional Estimates & Trend Analysis
- 8.1. Antipsychotic Drugs Market Share, By Region, 2023 & 2030 (USD Million)
- 8.2. North America
- 8.2.1. North America Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.2. U.S.
- 8.2.2.1. U.S. Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.3. Canada
- 8.2.3.1. Canada Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.4. Mexico
- 8.2.4.1. Mexico Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3. Europe
- 8.3.1. Europe Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. U.K.
- 8.3.2.1. U.K. Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Germany
- 8.3.3.1. Germany Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. France
- 8.3.4.1. France Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Italy
- 8.3.5.1. Italy Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6. Spain
- 8.3.6.1. Spain Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.7. Denmark
- 8.3.7.1. Denmark Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.8. Sweden
- 8.3.8.1. Sweden Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.9. Norway
- 8.3.9.1. Norway Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. China
- 8.4.2.1. China Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Japan
- 8.4.3.1. Japan Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. India
- 8.4.4.1. India Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. Australia
- 8.4.5.1. Australia Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.6. South Korea
- 8.4.6.1. South Korea Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.7. Thailand
- 8.4.7.1. Thailand Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5. Latin America
- 8.5.1. Latin America Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Brazil
- 8.5.2.1. Brazil Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Argentina
- 8.5.3.1. Argentina Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6. Middle East and Africa
- 8.6.1. Middle East and Africa Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Saudi Arabia
- 8.6.2.1. Saudi Arabia Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. UAE
- 8.6.3.1. UAE Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. South Africa
- 8.6.4.1. South Africa Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Kuwait
- 8.6.5.1. Kuwait Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis by Key Market Participants
- 9.2. Company Categorization
- 9.3. Company Heat Map Analysis
- 9.4. Company Profiles
- 9.4.1. H.Lundbeck A/S
- 9.4.1.1. Participant's Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Recent Developments/ Strategic Initiatives
- 9.4.2. Otsuka Pharmaceutical Co., Ltd.
- 9.4.2.1. Participant's Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Recent Developments/ Strategic Initiatives
- 9.4.3. Janssen Global Services, LLC
- 9.4.3.1. Participant's Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Recent Developments/ Strategic Initiatives
- 9.4.4. Eli Lilly and Company
- 9.4.4.1. Participant's Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Recent Developments/ Strategic Initiatives
- 9.4.5. AbbVie, Inc.
- 9.4.5.1. Participant's Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Recent Developments/ Strategic Initiatives
- 9.4.6. Teva Pharmaceutical Industries Ltd.
- 9.4.6.1. Participant's Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Product Benchmarking
- 9.4.6.4. Recent Developments/ Strategic Initiatives
- 9.4.7. Dr. Reddy's Laboratories Ltd.
- 9.4.7.1. Participant's Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Recent Developments/ Strategic Initiatives
- 9.4.8. Sumitomo Pharma
- 9.4.8.1. Participant's Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Recent Developments/ Strategic Initiatives
- 9.4.9. Alkermes
- 9.4.9.1. Participant's Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Recent Developments/ Strategic Initiatives
- 9.4.10. Bristol-Myers Squibb Company
- 9.4.10.1. Participant's Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Recent Developments/ Strategic Initiatives
- 9.4.1. H.Lundbeck A/S
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.